Exagen shared its third-quarter sales of $18.4 million, showing an 11% growth this year.

Nov 10, 2026, 9:19 AM ETResultsRead the original at Benzinga

Good for XGN

Exagen reported record Q3 sales, year-to-date sales growth and improved adjusted EBITDA, and kept its full-year sales forecast. Its ATM use may add shares, but the reported business growth outweighs that concern.

XGN · Exagen

AI read · Good for XGN

The AI's read

The reported growth came with higher test volume and a record average selling price. Exagen also kept its full-year sales forecast and is preparing a new test for early 2027. Its use of an ATM facility strengthened its balance sheet and brought in investors. It may also add shares, but the call gave no amount. The reported business growth is the stronger signal.

Get alerts for XGN

Follow Exagen (XGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for XGN

Free on the App Store and Google Play, or on the web.